Cartilage repair therapeutics - Ocugen/Precigen Inc
Alternative Names: Induced pluripotent stem cells derived therapeutics - Ocugen/Precigen; iPSC derrived therapeutics - Ocugen/Precigen IncLatest Information Update: 07 Feb 2020
Price :
$50 *
At a glance
- Originator Histogenics Corporation
- Developer Ocugen; Precigen Inc
- Class Cell therapies
- Mechanism of Action Cartilage replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cartilage disorders
Most Recent Events
- 03 Feb 2020 Intrexon Corporation is now called Precigen Inc
- 30 Sep 2019 Histogenics Corporation and Ocugen has merged to form Ocugen
- 28 Nov 2018 No recent reports of development identified for research development in Cartilage-disorders in USA (Parenteral)